Mood Stabilizers: Lithium, Valproate, and Lamotrigine — How They Work, What to Expect, and Evidence for Effectiveness

Mood stabilizers are a class of psychiatric medications primarily used to reduce the severity and frequency of extreme mood episodes — both the highs (mania or hypomania) and lows (depressive episodes) — that characterize bipolar spectrum disorders. Unlike antidepressants, which primarily target depressive symptoms, or antipsychotics, which primarily target psychotic and manic symptoms, mood stabilizers are distinguished by their ability to regulate mood in both directions without triggering a switch to the opposite pole.

The three most widely prescribed and best-studied mood stabilizers are:

• Lithium (lithium carbonate or lithium citrate) — the oldest and most extensively researched mood stabilizer, considered the gold standard for bipolar I disorder
• Valproate (valproic acid, divalproex sodium, sodium valproate) — an anticonvulsant with broad mood-stabilizing properties, marketed under brand names such as Depakote and Depakene
• Lamotrigine (Lamictal) — an anticonvulsant particularly effective for the depressive phase of bipolar disorder

Each of these medications has a distinct pharmacological profile, meaning they work through different mechanisms, are effective for different phases of illness, and carry different side effect profiles. Understanding these differences is essential for anyone seeking to learn about their treatment options.

The precise mechanisms through which mood stabilizers exert their effects are complex and, in some cases, not fully understood. However, decades of research have revealed important information about each medication's pharmacology.

Lithium

Lithium is a naturally occurring element — the lightest solid metal on the periodic table — and its mood-stabilizing properties were first documented in 1949 by Australian psychiatrist John Cade. Lithium affects multiple neurotransmitter systems and intracellular signaling pathways simultaneously. Key mechanisms include:

• Inhibition of inositol monophosphatase and glycogen synthase kinase-3 (GSK-3): These enzymes are involved in intracellular signaling cascades that regulate neuronal excitability, gene expression, and cell survival. By modulating these pathways, lithium appears to stabilize neuronal activity.
• Modulation of glutamate and GABA neurotransmission: Lithium reduces excitatory glutamate signaling and enhances inhibitory GABA activity, producing an overall stabilizing effect on neural circuits.
• Neuroprotective effects: Research demonstrates that lithium increases levels of brain-derived neurotrophic factor (BDNF) and promotes neuronal survival, which may partly explain its long-term protective benefits.

Valproate

Valproate was originally developed as an anticonvulsant and was serendipitously found to have mood-stabilizing properties. Its mechanisms include:

• Enhancement of GABAergic transmission: Valproate increases brain concentrations of gamma-aminobutyric acid (GABA), the brain's primary inhibitory neurotransmitter, by inhibiting GABA degradation and enhancing GABA synthesis.
• Blockade of voltage-gated sodium channels: This reduces rapid neuronal firing, which is thought to contribute to mood stabilization.
• Histone deacetylase (HDAC) inhibition: Valproate alters gene expression through epigenetic mechanisms, which may contribute to its longer-term mood-stabilizing effects.

Lamotrigine

Lamotrigine is also an anticonvulsant repurposed for mood stabilization. Its primary mechanisms include:

• Inhibition of voltage-gated sodium channels: This stabilizes neuronal membranes and reduces the release of excitatory neurotransmitters, particularly glutamate.
• Reduction of glutamate release: Excessive glutamate activity has been implicated in the neurobiology of bipolar depression, and lamotrigine's ability to dampen this excitatory signaling is thought to underlie its antidepressant effect within bipolar disorder.

It is important to understand that these medications do not "fix" a single broken chemical. Rather, they modulate complex neural networks and signaling pathways, producing a net effect of mood stabilization over time.

Mood stabilizers are primarily prescribed for bipolar and related disorders, though they have several additional clinical applications.

Bipolar I Disorder

The DSM-5-TR defines bipolar I disorder by the occurrence of at least one manic episode — a period of abnormally elevated, expansive, or irritable mood with increased energy lasting at least seven days (or any duration if hospitalization is required). Lithium and valproate are first-line treatments for acute manic episodes and long-term maintenance. Lithium is the only mood stabilizer with robust evidence for reducing suicide risk in bipolar I disorder. Lamotrigine is primarily used for maintenance therapy, particularly to prevent depressive recurrence, rather than to treat acute mania.

Bipolar II Disorder

Bipolar II disorder is characterized by recurrent depressive episodes and at least one hypomanic episode (a less severe form of mania lasting at least four days). Because the depressive burden is typically the predominant clinical concern in bipolar II, lamotrigine is particularly valuable in this population. Lithium is also used, with evidence supporting its efficacy for bipolar II maintenance.

Cyclothymic Disorder

Cyclothymic disorder involves chronic, fluctuating mood disturbance with numerous periods of hypomanic and depressive symptoms that do not meet full criteria for bipolar I or II. Mood stabilizers, particularly lithium, are sometimes used when symptoms cause significant functional impairment.

Schizoaffective Disorder

When prominent mood episodes co-occur with psychotic features, mood stabilizers are often used as adjunctive therapy alongside antipsychotics.

Other Clinical Uses

• Adjunctive treatment for major depressive disorder (MDD): Lithium augmentation — adding lithium to an antidepressant — is one of the most evidence-supported strategies for treatment-resistant depression.
• Seizure disorders: Valproate and lamotrigine retain their FDA-approved indications for epilepsy.
• Impulse control and aggression: Mood stabilizers, particularly valproate, are sometimes used off-label to manage aggression and emotional dysregulation in various clinical contexts, though evidence for these applications varies.

Starting a mood stabilizer involves several important phases, and understanding the timeline and process helps set realistic expectations.

Initial Assessment

Before prescribing a mood stabilizer, a clinician will typically conduct a comprehensive psychiatric evaluation, review medical history, and order baseline laboratory tests. For lithium, this includes renal function tests (BUN, creatinine), thyroid function (TSH), a complete blood count, and an electrocardiogram in patients over 40 or with cardiac risk factors. For valproate, baseline liver function tests and a complete blood count are standard. Lamotrigine generally requires fewer baseline labs but a thorough skin examination and medication interaction review are important.

Titration Phase

Mood stabilizers are typically started at low doses and gradually increased — a process called titration. This is especially critical for lamotrigine, which must be increased very slowly (usually over six or more weeks) to minimize the risk of a serious skin reaction called Stevens-Johnson syndrome. Lithium is usually titrated to achieve a target blood level, typically 0.6–1.0 mEq/L for maintenance and sometimes 0.8–1.2 mEq/L for acute mania. Valproate is titrated to achieve blood levels of 50–125 mcg/mL.

Onset of Therapeutic Effects

For acute mania, lithium and valproate typically begin showing effects within 1–2 weeks, though full stabilization may take longer. Lamotrigine's antidepressant effects in bipolar disorder generally require 4–8 weeks at therapeutic doses, partly because the slow titration schedule delays reaching the effective dose range (typically 100–200 mg/day).

Ongoing Monitoring

Mood stabilizer treatment requires regular monitoring:

• Lithium: Blood levels every 1–2 weeks during initiation, then every 3–6 months once stable. Kidney function and thyroid function are monitored every 6–12 months. Lithium has a narrow therapeutic index, meaning the difference between an effective dose and a toxic dose is relatively small.
• Valproate: Blood levels, liver function, and complete blood count are monitored periodically, especially in the first six months.
• Lamotrigine: Routine blood level monitoring is not typically required, but patients must be educated about watching for any skin rash, especially during the first few months.

Duration of Treatment

Bipolar disorder is generally a lifelong condition, and clinical guidelines from the American Psychiatric Association (APA), the Canadian Network for Mood and Anxiety Treatments (CANMAT), and the National Institute for Health and Care Excellence (NICE) all recommend long-term or indefinite maintenance therapy for most patients after a clear diagnosis is established. Discontinuation should only occur under close medical supervision, as abrupt cessation — particularly of lithium — is associated with a high risk of relapse.

Mood stabilizers are among the most rigorously studied medications in psychiatry. Their evidence base spans decades and includes numerous randomized controlled trials, meta-analyses, and long-term observational studies.

Lithium

Lithium has the strongest overall evidence base of any mood stabilizer. Key findings include:

• Acute mania: Multiple meta-analyses confirm lithium's superiority over placebo for treating acute manic episodes, with response rates typically in the range of 40–80% depending on the study and population.
• Maintenance therapy: A landmark Cochrane meta-analysis found that lithium reduces the risk of manic relapse by approximately 38% and depressive relapse by approximately 28% compared to placebo.
• Anti-suicidal effects: Lithium is the only psychiatric medication with consistent evidence of reducing suicide risk. A meta-analysis published in the British Journal of Psychiatry found that lithium reduces the risk of suicide and self-harm by approximately 60% in people with mood disorders. This property is unique among mood stabilizers and is a significant factor in treatment selection.
• Neuroprotection: Neuroimaging studies show that long-term lithium treatment is associated with greater cortical gray matter volume compared to other treatments, suggesting possible neuroprotective effects.

Valproate

• Acute mania: Valproate is established as effective for acute mania and is considered comparable to lithium in many guidelines. It may be particularly effective for mixed episodes (simultaneous manic and depressive features) and rapid cycling.
• Maintenance therapy: The evidence for valproate in long-term maintenance is less robust than for lithium. The BALANCE trial, a large randomized controlled trial published in The Lancet, found lithium monotherapy superior to valproate monotherapy for preventing mood episodes over two years, though the combination was comparable to lithium alone.

Lamotrigine

• Bipolar depression prevention: Two pivotal 18-month randomized controlled trials demonstrated that lamotrigine significantly extends the time to depressive relapse compared to placebo. It is considered a first-line agent for bipolar depression prevention by CANMAT, NICE, and APA guidelines.
• Acute bipolar depression: Evidence for lamotrigine as an acute treatment for bipolar depression is mixed. Some individual trials showed benefit, but meta-analyses have yielded inconsistent results, possibly due to the slow titration schedule limiting dose optimization within short trial periods.
• Mania: Lamotrigine has no established efficacy for treating or preventing manic episodes and should not be used as monotherapy where mania prevention is the primary goal.

Overall, the evidence supports a complementary role for these three medications: lithium as the most broadly effective mood stabilizer with unique anti-suicidal properties, valproate as particularly useful for acute mania and mixed features, and lamotrigine as the leading agent for bipolar depression prevention.

Each mood stabilizer carries a distinct side effect profile, and understanding these is essential for informed treatment decisions.

Lithium Side Effects

• Common: Increased thirst and urination (polyuria/polydipsia), fine hand tremor, weight gain (typically 4–10 pounds), gastrointestinal discomfort, mild cognitive dulling (sometimes described as "mental fog")
• Long-term risks: Chronic kidney disease (affects approximately 15–20% of long-term users to some degree), hypothyroidism (occurs in up to 25% of patients, treatable with thyroid supplementation), hyperparathyroidism
• Toxicity: Lithium toxicity is a medical emergency. Symptoms include severe tremor, confusion, vomiting, diarrhea, ataxia, and in severe cases, seizures, coma, and death. Dehydration, nonsteroidal anti-inflammatory drugs (NSAIDs), certain blood pressure medications (ACE inhibitors, ARBs), and diuretics can dangerously elevate lithium levels.

Valproate Side Effects

• Common: Nausea, weight gain (often more significant than with lithium), tremor, hair thinning or loss, sedation
• Serious risks: Hepatotoxicity (liver damage, particularly in children under two), pancreatitis (rare but potentially fatal), thrombocytopenia (low platelet count), polycystic ovary syndrome (PCOS) — valproate has been associated with hormonal changes and metabolic effects that may contribute to PCOS in women of reproductive age
• Teratogenicity: Valproate is a known teratogen with the highest risk of birth defects among commonly prescribed psychiatric medications. The risk of major congenital malformations, including neural tube defects, is approximately 10%, and the risk of neurodevelopmental effects including lower IQ is well-documented. Valproate is contraindicated during pregnancy, and prescribers are required to counsel women of childbearing potential about these risks. In many countries, prescribing valproate to women of childbearing age requires participation in a risk management program.

Lamotrigine Side Effects

• Common: Headache, dizziness, nausea, blurred vision, insomnia or somnolence. Notably, lamotrigine is generally considered weight-neutral and cognitively well-tolerated, making it one of the better-tolerated mood stabilizers.
• Serious risks: The primary safety concern is Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) — severe, potentially life-threatening skin reactions. The risk is estimated at approximately 0.08–0.1% in adults when proper titration guidelines are followed, but rises significantly with rapid dose escalation or concurrent use of valproate (which raises lamotrigine blood levels). Any rash developing during lamotrigine initiation warrants immediate medical evaluation.

General Limitations of Mood Stabilizers

• They require regular blood monitoring (especially lithium and valproate)
• They do not work immediately — patience during the titration and stabilization period is necessary
• None of them are universally effective — approximately 30–40% of individuals with bipolar disorder do not achieve full remission with a single mood stabilizer
• Adherence can be challenging due to side effects or the subjective experience of "missing" hypomanic energy

Mood stabilizers are prescription medications that require management by a qualified healthcare professional. The following clinicians can prescribe and monitor mood stabilizer treatment:

• Psychiatrists (MD or DO): The most appropriate specialists for complex mood stabilizer management, particularly when diagnostic questions remain or multiple medications are involved
• Psychiatric nurse practitioners (PMHNPs): Advanced practice nurses with specialized training in psychiatric medication management
• Primary care physicians: Some family medicine and internal medicine physicians manage mood stabilizers, though complex cases typically benefit from specialist involvement

Finding a provider:

• Insurance directories: Contact your insurance company or use their online provider directory to find in-network psychiatrists
• Psychology Today's "Find a Psychiatrist" tool allows filtering by insurance, specialty, and location
• SAMHSA's National Helpline (1-800-662-4357) provides free referrals to local treatment services
• Community Mental Health Centers (CMHCs): Federally supported centers that provide psychiatric services on a sliding-scale fee basis
• Academic medical centers: University-affiliated psychiatry departments often have mood disorder specialty clinics with expertise in complex mood stabilizer management
• Telehealth platforms: Several platforms now offer psychiatric medication management via video visits, which can improve access for those in underserved areas, though lithium monitoring still requires access to local laboratory services

When seeking a provider for mood stabilizer management, it is reasonable to ask about their experience treating bipolar disorder, their approach to monitoring and follow-up, and how they handle between-appointment concerns.

All three major mood stabilizers are available as generics, which significantly improves their affordability compared to newer branded psychiatric medications.

Approximate Monthly Costs (Generic, Without Insurance)

• Lithium carbonate: $10–$30 per month at typical maintenance doses
• Divalproex sodium (generic Depakote): $15–$50 per month
• Lamotrigine (generic Lamictal): $10–$40 per month

These are among the most affordable psychiatric medications available. However, the total cost of treatment includes more than the medication itself:

• Laboratory monitoring: Blood draws for lithium levels, kidney function, thyroid function, liver function, and blood counts can add $100–$300 or more per year depending on insurance coverage and frequency of testing
• Psychiatry appointments: Follow-up visits typically occur every 1–3 months once stable, and costs vary widely based on insurance status and provider type
• Pharmacy discount programs: GoodRx, RxAssist, and manufacturer patient assistance programs can substantially reduce costs for uninsured or underinsured patients

Insurance Coverage

Mood stabilizers are covered by virtually all insurance plans, including Medicaid and Medicare, due to their generic availability and established clinical necessity. The Mental Health Parity and Addiction Equity Act requires that coverage for mental health medications be comparable to coverage for other medical conditions.

Access Barriers

The most significant barrier to mood stabilizer treatment is often not the medication cost but access to psychiatric care. The United States faces a significant shortage of psychiatrists, particularly in rural areas. Wait times for an initial psychiatric evaluation can range from several weeks to several months in some regions. Community mental health centers, integrated primary care models, and telepsychiatry are helping to address this gap, but disparities persist.

When mood stabilizers are insufficient, poorly tolerated, or contraindicated, several alternative or adjunctive treatment approaches exist:

Atypical Antipsychotics

Second-generation (atypical) antipsychotics — including quetiapine, olanzapine, aripiprazole, lurasidone, and cariprazine — have FDA-approved indications for various phases of bipolar disorder. Quetiapine has strong evidence for both bipolar mania and bipolar depression. Lurasidone and cariprazine are approved specifically for bipolar depression. These are increasingly used either as alternatives to or in combination with traditional mood stabilizers.

Carbamazepine and Oxcarbazepine

Carbamazepine (Tegretol) is another anticonvulsant with evidence for acute mania, though drug interactions and side effects limit its use. Oxcarbazepine (Trileptal) is sometimes used as a better-tolerated alternative, though its evidence base for bipolar disorder is less established.

Psychotherapy

Psychotherapy is not a replacement for mood stabilizers in bipolar disorder, but it is a critical adjunctive treatment. Evidence-based therapies include:

• Cognitive Behavioral Therapy (CBT): Helps identify and modify cognitive distortions and develop coping strategies for mood episodes
• Interpersonal and Social Rhythm Therapy (IPSRT): Specifically developed for bipolar disorder, focuses on stabilizing daily routines and circadian rhythms
• Family-Focused Therapy (FFT): Involves family members in treatment to improve communication, reduce expressed emotion, and enhance treatment adherence
• Psychoeducation: Structured education about the illness has been shown to significantly reduce relapse rates when combined with medication

Electroconvulsive Therapy (ECT)

ECT remains one of the most effective treatments for severe bipolar depression and treatment-resistant mania. It is typically reserved for cases where medications have failed or where the clinical situation requires a rapid response (such as severe suicidal ideation or catatonia).

Lifestyle Interventions

While not substitutes for pharmacotherapy in bipolar disorder, consistent sleep-wake schedules, regular physical activity, stress management, avoidance of alcohol and recreational substances, and mood monitoring are evidence-supported strategies that complement medication treatment.

If you are experiencing patterns consistent with significant mood instability — such as periods of unusually elevated energy, decreased need for sleep, impulsive behavior, grandiosity, or racing thoughts alternating with periods of depression — a professional evaluation is an important first step. Bipolar disorder is frequently misdiagnosed as unipolar depression, and receiving the wrong treatment (such as antidepressants without a mood stabilizer) can worsen outcomes.

Seek immediate medical attention if:

• You are experiencing thoughts of suicide or self-harm — call the 988 Suicide and Crisis Lifeline (call or text 988) or go to your nearest emergency room
• You are taking lithium and develop severe tremor, confusion, persistent vomiting, or difficulty walking — these may indicate lithium toxicity
• You are taking lamotrigine and develop any skin rash, especially one accompanied by fever, mouth sores, or blistering
• You are experiencing symptoms of mania that are impairing your judgment, putting you at risk, or causing significant interpersonal or occupational problems

A thorough psychiatric evaluation — including a detailed mood history, family history, and sometimes collateral information from family members — is the foundation for accurate diagnosis and appropriate treatment selection. Mood stabilizers can be profoundly effective medications, but they work best within the context of a comprehensive treatment plan guided by a knowledgeable clinician.